Europe Liver Cancer Therapeutics Market - 2023-2030

Europe Liver Cancer Therapeutics Market - 2023-2030

Market Overview

The Europe liver cancer therapeutics size was valued at US$ 384 million in 2022 and is estimated to reach US$ 627 million by 2030, growing at a CAGR of 8.95% during the forecast period (2023-2030).

Liver cancer is a chronic, life-threatening, advanced condition that initiates in liver cells. The liver is the critical organ in the human body, found in the upper right of the abdomen underneath the right of the lungs. The liver produces enzymes and bile to digest food. It also delivers blood-clotting proteins and clarifies the blood by removing harmful materials.

Market Dynamics

Market drivers include the availability of novel drugs, a strong pipeline basis, and growing efforts for early diagnosis of HCC. Unhealthy lifestyles and a growing geriatric population are driving the growth of the liver cancer therapeutics market.

The growing cases of liver cancer drive Europe’s market growth.

According to the European Commission, around three-quarters of European liver cancer patients are of a kind known as hepatocellular carcinoma, which, when analyzed late, sees only one in 10 victims survive five years or more. Also, according to the European Association for the Study of the Liver, more than 98,000 persons in Europe are diagnosed with liver cancer yearly, while around 89,000 die from it. Late diagnosis is a serious problem, as up to half of the patients are diagnosed with an advanced cancer stage. Therefore, prevention and early detection are crucial to beat liver cancer. According to Global Policy Reporting, there has been a 70% increase in liver cancer-related mortality in Europe in the past two decades. Over 87,000 Europeans were diagnosed with liver cancer, while 78,000 died in 2020.

Furthermore, different initiatives taken by various organizations to fight against Europe's liver cancer situation contribute towards market growth during the forecast period. For instance, In June 2021, EASL and the scientific liver health community in Europe called for implementing measures to improve liver cancer care in Europe. Also, Ambitious Europe's Beating Cancer Plan and the EU4Health program must be the basis for improving patients with liver cancer care. Thus, the growing cases of liver cancer and initiatives by European organizations to fight against liver cancer are promoting market growth in the forecast period.

The high cost of liver cancer diagnosis and treatment in Europe is restraining the Europe liver cancer therapeutics market growth.

However, the high cost of liver cancer diagnosis and treatment in Europe is hampering the market growth. For instance, according to Booking Health GmbH, the cost of treatment with chemoembolization starts at €4,711. The price for unilateral hepatectomy starts at €12,076. The cost of radiofrequency ablation starts at €4,687.

COVID-19 Impact.

The prognosis of patients with HCC largely depends on the stage of underlying liver disease. Measures for the care of patients with the liver disease during the COVID-19 pandemic have recently been proposed by the European Association for the Studies of the Liver (EASL). Under this, the patients with decompensated liver disease, patients on the waiting list for liver transplantation, patients with suspected HCC, patients with proven HCC awaiting treatment initiation or modification, and patients showing moderate or severe side effects to treatment were kept on high priority. Such initiatives by European organizations to manage liver cancer patients during the pandemic lessened the negative impact of the pandemic on the market.

Segment Analysis

Chemotherapy is expected to have a greater grasp of the liver cancer therapeutics market during the forecast period (2022-2029)

The chemotherapy segment is anticipated to dominate the Europe Liver cancer therapeutics market, owing to the increased research activities focused on chemotherapy. For instance, according to an article from Pan European Networks Ltd, published in October 2022, a new drug discovered by the University of Barcelona can inhibit cell division and growth in enzymes and could revolutionize liver cancer treatment. Also, in January 2023, The European Medicines Agency’s Committee for Medicinal Products for Human Use gave a positive opinion on the use of durvalumab (Imfinzi) combined with tremelimumab (Imjudo) to treat advanced lung and liver cancers, according to a press release from AstraZeneca. Therefore, the mentioned data indicates that the chemotherapy segment will dominate the Europe liver cancer therapeutics market during the forecast period.

Geographical Analysis

Germany is expected to command dominating the Europe liver cancer therapeutics market.

Germany is estimated to hold most of the Europe liver cancer therapeutics market in the forecast period, owing to the increasing research activities in this country and the growing liver cancer cases. For instance, in August 2022, Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Hebrew University in Jerusalem identified the cell of origin in mice of combined liver/biliary duct carcinomas, a rare type of cancer of the liver. The pro-inflammatory immune messenger interleukin 6 (IL-6) was found to be the driver of carcinogenesis. Blocking of IL-6 reduced both the number and size of tumors in mice. Moreover, According to The Robert Koch Institute, a Federal Institute within the Federal Ministry of Health portfolio, in Germany, there were about 9,500 new cases per year, with about 8,000 deaths. On average, men are diagnosed at 71 years and women at 75. Thus, the mentioned data indicates that Germany will hold most of the Europe liver cancer therapeutics market throughout the forecast period.

Competitive Landscape

The key players operating in the Europe Liver Cancer Therapeutics market are Amgen Inc., AstraZeneca PLC, Bayer AG, Celgene Corporation, Eli Lilly, Bristol-Myers Squibb Company, Gilead Sciences, Inc., Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company, Limited, and UCB SA. among others. The key players are embracing various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the Liver Cancer Therapeutics market in Europe. For instance, in December 2022, AstraZeneca’s Imfinzi (durvalumab) was approved in the European Union (EU) for the 1st-line treatment of adult patients with unresectable or metastatic biliary tract cancer (BTC) in combination with chemotherapy (gemcitabine plus cisplatin).

Amgen Inc.

Overview:

Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures, and markets medicines for grievous illnesses. The Company focuses solely on human therapeutics and innovates novel medicines based on cellular and molecular biology advances.

Product Portfolio:

The Company’s portfolio comprises inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas.

The Europe liver cancer therapeutics report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.